Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 2282 | 4.06 |
09:34 ET | 1500 | 4.2 |
09:38 ET | 983 | 4.195 |
09:41 ET | 1015 | 4.1999 |
09:50 ET | 126 | 4.1504 |
09:52 ET | 449 | 4.11 |
11:29 ET | 200 | 4.11 |
11:31 ET | 100 | 4.055 |
11:58 ET | 7588 | 4.21 |
01:10 ET | 100 | 4.14 |
01:14 ET | 1000 | 4.115 |
02:13 ET | 200 | 4.13 |
02:15 ET | 122 | 4.11 |
03:30 ET | 150 | 4.1357 |
03:59 ET | 528 | 4.12 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 226.3M | -2.2x | --- |
Acumen Pharmaceuticals Inc | 230.7M | -3.6x | --- |
INmune Bio Inc | 222.2M | -5.9x | --- |
Compass Therapeutics Inc. | 220.1M | -4.6x | --- |
Ovid Therapeutics Inc | 222.3M | -4.4x | --- |
Boundless Bio Inc | 236.2M | 0.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $226.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.